Last reviewed · How we verify
Zofran®
At a glance
| Generic name | Zofran® |
|---|---|
| Also known as | Ondansetron ODT, Ondansetron, Odanesetron, ondansetron |
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Assessment of Endotracheal Tube Temperature Effects in Children Undergoing Adenotonsillectomy (NA)
- Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (PHASE4)
- Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (PHASE3)
- Effects of Binaural Beats on Inhaled Anesthetic Requirements During General Anesthesia in Pediatric Patients (NA)
- Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy (NA)
- Buprenorphine-Fentanyl Interaction Study (PHASE1)
- The Impact of Helfer Skin Tap and ShotBlocker Techniques on Emotional Responses to Intramuscular Injections in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zofran® CI brief — competitive landscape report
- Zofran® updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI